Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Aehr Test Systems

Onconova Therapeutics

Uxin Ltd - ADR

Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?

Top Penny Stocks to Buy Now? 4 Big Movers to Watch Today

This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As clinical data continues to strengthen, Immutep is seemingly well situated for potential takeout or large biobucks deal(s).

Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout

Aikido Pharma Inc.

Actinium Pharmaceuticals

Atossa Genetics

Bionano Genomics

CTI BioPharma

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on its clinical and preclinical programs.

Immutep Operational Update

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology's (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June.

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2020 fiscal year, mainly related to the Company's TACTI-mel  and TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Immutep Receives A$1,155,055 R&D Tax Incentive

Investors liked the company's latest regulatory update.

Why Immutep Limited Stock Popped Today

Immutep jumped as much as 13% to two-week highs on Thursday after the biotechnology company announced that its lead drug candidate for recurrent or metastatic head and neck cancer has received a fast track status from the US Food and Drug Administration. Immutep was up 8% to $3.45 as of 12:00 p.m. ET, having risen to a session peak of $3.59 earlier in the day, its highest since March 25.

Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer (IMMP)

Aprea Therapeutics

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia. Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics.

What's Going On With APRE Stock And IMMP Stock Today?

IMMP stock is getting a boost in Thursday trading after European regulators gave one of its cancer antibodies a key patent. The post IMMP Stock: The Big Patent News Boosting Immutep Today appeared first on InvestorPlace.

IMMP Stock: The Big Patent News Boosting Immutep Today

Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces its lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, has received Fast Track designation in 1st line recurrent or metastatic HNSCC from the United States Food and Drug Administration (FDA).

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

The stock price of Immutep Limited (NASDAQ: IMMP) increased by over 20% pre-market. This is why it happened.

Immutep Stock Price Increased Over 20% Pre-Market: Why It Happened

Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number EP3317301 entitled “Combination therapies comprising antibody molecules to LAG-3” by the European Patent Office.

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Immutep was one of the Benzinga Biotech Small Cap Conference held virtually on March 24 & 25, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

Biotech Immunotherapy Company Immutep Sets the Standard with its LAG-3 Research

Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing Higher Today?

IMMP Stock: Why Is Biotech Company Immutep Rocketing Higher Today?

Cellect Biotechnology Ltd

Evofem Biosciences Inc

F-Star Therapeutics Inc

ProQR Therapeutics

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday

The stock price of Immutep (NASDAQ: IMMP) has increased by over 20% pre-market. This is why it happened.

IMMP Stock Price Increases Over 20% Pre-Market: Why It Happened

Sydney, AUSTRALIA, March 17, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the  Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC.  The conference will take place from 9:00 am - 5:00 pm on March 17th- 19th EST and will feature roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats and live Q&A.

Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference

Merck

Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients.

Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer Study

Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). Under the agreement, Immutep will conduct a new Phase IIb clinical trial in 1st line HNSCC patients, as initially described in the ASX announcement dated 28 September 2020.

Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer

Follows positive efficacy and safety review Follows positive efficacy and safety review

Immutep Expands Part B of TACTI-002 Study

Immutep's Collaboration and Exclusive License with GSK Remains in Place Immutep's Collaboration and Exclusive License with GSK Remains in Place

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study.

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office.

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Greenwich Lifesciences

SELLAS Life Sciences Group

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for effective treatments.

News for Immutep Ltd Stock (IMMP)